Search results for "AEM"

showing 10 items of 1006 documents

AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS

2000

H-IL-6 is a hybrid protein constructed to contain IL-6 and its soluble receptor linked by a flexible peptide chain. Here we show that H-IL-6 strongly enhances proliferation of human CD34(+)cells in serum-free liquid culture, and that the majority of the cells generated belong to the erythroid lineage, being positive for the marker Glycophorin A. Conversely, H-IL-6 does not increase the number of myeloid, CD13-positive cells. Comparable effects are observed on progenitors from cord blood and adult peripheral blood. Therefore, H-IL-6 triggers an erythroid-inducing signal in haematopoietic progenitor cells, independently from erythropoietin (EPO).

ErythrocytesTime FactorsMyeloidCellular differentiationInterleukin 6Antigens CD34BiochemistryCulture Media Serum-FreeSerum-Freehemic and lymphatic diseasesReceptorsLeukocytesImmunology and AllergyErythropoiesisGlycophorinsStem Cell FactorbiologyChemistryCord bloodCell DifferentiationHematologyFetal BloodFlow CytometryEndothelial stem cellHaematopoiesismedicine.anatomical_structureGlycophorinCD34+medicine.drugRecombinant Fusion ProteinsMononuclearImmunologyCD13 AntigensmedicineHumansGlycophorinAntigensProgenitor cellErythropoietinMolecular BiologyInterleukin 3Interleukin-6CD34+; Cord blood; Erythropoiesis; Interleukin 6; Stem cell factor; Antigens CD34; CD13 Antigens; Cell Differentiation; Culture Media Serum-Free; Erythrocytes; Erythropoietin; Fetal Blood; Flow Cytometry; Glycophorin; Hematopoietic Stem Cells; Humans; Interleukin-6; Leukocytes Mononuclear; Peptides; Receptors Interleukin-6; Recombinant Fusion Proteins; Stem Cell Factor; Time Factors; Immunology and Allergy; Immunology; Biochemistry; Hematology; Molecular BiologyHematopoietic Stem CellsReceptors Interleukin-6Molecular biologyCulture MediaErythropoietinLeukocytes Mononuclearbiology.proteinCD34PeptidesCytokine
researchProduct

Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?

2020

Introduction Certain haemophilia carriers demonstrate an increased bleeding tendency, mainly related to clotting factor deficiency. No study has so far formally compared the bleeding phenotype of women and girls with mild FVIII or FIX deficiency and associated management with that of male patients affected by mild haemophilia A and B. Material and methods We retrospectively evaluated 44 women and girls with mild FVIII or FIX deficiency (FVIII or FIX 0.05-0.5 IU/mL) and 77 male patients with mild haemophilia A or B and compared them with respect to clotting factor level, age at and trigger for diagnosis, as well as treatment modalities. Results After excluding gender-related haemorrhagic sym…

FVIIImild haemophiliaAdultMalePediatricsmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesHeterozygoteAdolescentMucocutaneous zonecarriersPlasma factorAge at diagnosis030204 cardiovascular system & hematologyHaemophiliaHemophilia AHemostatics03 medical and health sciencesYoung Adult0302 clinical medicinecarrierhemic and lymphatic diseasesmedicineHumansDeamino Arginine VasopressinClotting factor deficiencyChildGenetics (clinical)AgedClotting factorAged 80 and overbusiness.industryFIXHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood Coagulation Factorsbleeding phenotypebleeding phenotype carriers FIX FVIII mild haemophiliaMale patientChild PreschoolMild haemophilia AFemalebusiness030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBi…

2020

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agen…

Factor VIIIFVIII inhibitorSettore BIO/12Antibodies Bispecific Antibodies Monoclonal Humanized Factor VIII Hemophilia A Hemorrhage Hemostatics Humans Italy Quality of LifeFVIII inhibitorsHemorrhageAntibodies Monoclonal HumanizedHemophilia AAntibodiesHemostaticsbypassing agents; emergency; emicizumab; FVIII inhibitors; haemophilia AItalyhemic and lymphatic diseasesMonoclonalEmergencyHaemophilia AAntibodies BispecificQuality of LifeHumansBispecificBypassing agentsEmicizumabHumanizedBypassing agentHaemostasis
researchProduct

Anaemia in advanced chronic fasciolosis

2008

Abstract The association between fasciolosis-induced anaemia and related factors has been quantified in a rodent model. Haematological parameters were analysed in Wistar rats at 20 and 60 weeks post-infection (p.i.). Pigment stones and bile specimens were collected. Serum IgG1, IgG2a and IgE were determined in rat serum samples. Cytokine levels have been correlated with haematological parameters. The screening for gastrointestinal bleeding was carried out. Bacteriological bile cultures revealed viable bacteria in 53.8% of specimens at 60 weeks p.i. The results show that the type of anaemia in fasciolosis might be considered a biomarker of the chronicity period of the disease, changing from …

Fascioliasismedicine.medical_specialtyAnemiaVeterinary (miscellaneous)Statistics as TopicAntibodies HelminthHelminthiasisPhysiologyBiologyFecesInternal medicinemedicineAnimalsBileFasciolosisRats WistarEggs per gramFecesCell SizeAnemia HypochromicMicrobial ViabilityHematologyBacteriaAnemiamedicine.diseaseHaemolysisRatsInfectious DiseasesInsect ScienceMultivariate AnalysisImmunologyErythropoiesisParasitologyBiomarkersSpleenActa Tropica
researchProduct

Schistosomiasis and water-related practices in school girls in rural KwaZulu-Natal, South Africa

2010

There is increasing evidence of an association between female genital Schistosoma haematobium infection and HIV. In KwaZulu-Natal, we aimed to explore girls' water contact practice and to determine...

Female circumcisionEpidemiologyHuman immunodeficiency virus (HIV)Waterborne diseasesSchistosomiasisDermatologyBiologymedicine.diseasemedicine.disease_causeInfectious DiseasesSchistosoma haematobium infectionEnvironmental healthparasitic diseasesImmunologymedicineHelminthsRural areaKwazulu natalSouthern African Journal of Epidemiology and Infection
researchProduct

In utero fetal liver hematopoietic stem cell transplantation: is there a role for alloreactive T lymphocytes?

2000

The use of hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy, although this approach has provided quite heterogeneous results. Flake and Zanjani have provided an excellent updated review of the current knowledge of in

FetusLiver cytologybusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistryIn utero transplantationHaematopoiesisIn uteroImmunologymedicineStem cellbusinessFetal therapyBlood
researchProduct

Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing…

2021

Abstract The bone marrow (BM) niche regulation and interactions with hematopoietic stem cells (HSC) have been extensively studied in steady state conditions and malignancies, but are still underexplored in hematological inherited disorders. We provided the first demonstration of impaired HSC function caused by an altered BM niche in a non-malignant disease, beta-thalassemia (BT) (Aprile et al., Blood 2020). BT is a globally widespread congenital hemoglobin disorder, resulting in severe anemia, ineffective erythropoiesis and multi-organ secondary complications, including bone alterations. Correction of the genetic defect is achieved by transplantation of HSC from healthy donors or autologous…

Fibroblast growth factor 23HaematopoiesisHematopoietic stem cell nicheImmunologymedicineBeta thalassemiaCell BiologyHematologyBiologymedicine.diseaseBiochemistryCell biologyBlood
researchProduct

Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results fro…

2019

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, potentially fatal disorder of haematopoietic stem cells caused by mutations in an X-linked gene called phosphatidylinositol glycan class A, characterised by intravascular haemolysis, bone marrow failure and thrombotic events. The disease can occur at any age, although preferentially it affects young adults; its estimated prevalence is about 1/500,000 [1]. Clinical symptoms are variable and can include haemolytic anaemia, moderate to severe impairment of haematopoiesis and, in approximately 40% of patients, thrombosis of the vessels of the abdomen, brain and skin [2]. Rare, atypical site thrombosis of the splanchnic veins or cerebral sinu…

First episodemedicine.medical_specialtybusiness.industryCross-sectional studyHemoglobinuria ParoxysmalThrombosisHematologymedicine.diseasePhenotypePeripheralVein thrombosisVenous thrombosisCross-Sectional StudiesPhenotypeInternal medicinemedicineCardiologyHumansParoxysmal nocturnal haemoglobinuriaRisk factorbusinessCerebral sinus venous thrombosisPNHRisk factorScreeningVenous thrombosis
researchProduct

Flavonoids from Acacia pennata and their Cyclooxygenase (COX-1 and COX-2) Inhibitory Activities

2007

Two new flavonoids quercetin 4'-O-alpha-L-rhamnopyranosyl-3-O-beta-D-allopyranoside (1) and apigenin 6-C-[2''-O-(E)-feruloyl- beta-D-glucopyranosyl]-8-C-beta-glucopyranoside (2), along with the known isorhamnetin 3-O-alpha-L-rhamnopyranoside (3), kaempferol 3-O-alpha-L-rhamnopyranosyl-(1-->4)-beta-D-glucopyranoside (4), and isovitexin (5) were isolated from the leaves of Acacia pennata Willd. (Mimosaceae) and tested for their anti-inflammatory activity. Their structures were determined by 1D and 2D NMR and mass spectrometry. They were tested for an inhibitory effect on COX-1 and COX-2, showing 60-90% inhibition at 10(-4) g/mL and 5-14% inhibition at 10(-4) g/mL, respectively.

FlavonoidIsovitexinPharmaceutical ScienceBiologyPharmacognosyAnalytical ChemistryInhibitory Concentration 50chemistry.chemical_compoundDrug DiscoveryHumansCyclooxygenase InhibitorsPhenolsIsorhamnetinPharmacologychemistry.chemical_classificationTraditional medicinePlant ExtractsOrganic ChemistryAcaciaFlavonesPlant LeavesComplementary and alternative medicinechemistryBiochemistryCyclooxygenase 2ApigeninCyclooxygenase 1Molecular MedicineKaempferolQuercetinPhytotherapyPlanta Medica
researchProduct